Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Main Street Financial Solutions LLC

Main Street Financial Solutions LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 13.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,430 shares of the medical instruments supplier’s stock after selling 512 shares during the period. Main Street Financial Solutions LLC’s holdings in Becton, Dickinson and Company were worth $836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ontario Teachers Pension Plan Board increased its holdings in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the last quarter. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after purchasing an additional 516,427 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 11.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after purchasing an additional 512,566 shares during the last quarter. Royal Bank of Canada increased its holdings in Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after purchasing an additional 473,914 shares during the last quarter. Finally, Morgan Stanley boosted its position in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after buying an additional 435,168 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.1 %

Shares of Becton, Dickinson and Company stock traded down $0.32 during trading on Friday, hitting $236.30. 1,785,047 shares of the stock were exchanged, compared to its average volume of 1,436,944. The stock has a market cap of $68.29 billion, a price-to-earnings ratio of 52.05, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. The firm’s 50-day moving average price is $238.15 and its 200 day moving average price is $239.03. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.86 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Upgrades and Downgrades

Separately, Barclays raised their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $281.40.

View Our Latest Stock Report on BDX

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. In the last three months, insiders sold 8,597 shares of company stock valued at $2,028,786. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.